Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology.
Basquiera AL, García MJ, Martinez Rolón J, Olmedo J, Laviano J, Burgos R, Caeiro G, Remaggi G, Raña P, Paoletti M, González CM, Fernández I, Pavlovsky A, Perusini MA, Rodriguez A, Guanchiale L, Carvani A, Mandrile L, Figueroa F, Vicente Reparaz A, Fragapane Mathus PN, Garate G, Fauque ME, Kantor G, Cruset S, Gonzalez Lorch JS, Szelagowski M, Giarini MP, Oliveira N, García MC, Ventriglia MV, Pereyra PH, Gutierrez DR, Kusminsky G, Troccoli J, Freitas MJ, Cranco S, Del V Sanchez N, Rey I, Funes ME, Jarchum S, Freue J, Miroli A, Guerrero O, López Ares L, Campestri R, Bove V, Salinas GN, Cabrejo M, Milone JH, Zabaljauregui S, Gotta D, Dupont JC, Stemmelin G. Basquiera AL, et al. Among authors: zabaljauregui s. Medicina (B Aires). 2021;81(4):536-545. Medicina (B Aires). 2021. PMID: 34453794 Free article. English.
PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A, Fernandez I, Kurgansky N, Prates V, Zoppegno L, Negri P, Milone G, Cerutti I, Zabaljauregui S, Mariano R, Grecco HF, Basquiera AL, Saba S, Rudoy S, Sackmann F, Castano V, Remaggi G, Cabrejo M, Roveri E, Casale MF, Cabane V, Taus R, Venturini C, Sakamoto F, Varela AI, Riddick M, Pavlovsky S; Grupo Argentino de tratamiento de Leucemia Aguda (GATLA), Argentina. Pavlovsky A, et al. Among authors: zabaljauregui s. Br J Haematol. 2019 Jun;185(5):865-873. doi: 10.1111/bjh.15838. Epub 2019 Mar 12. Br J Haematol. 2019. PMID: 30864146 Free article.
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple.
Duarte PJ, Schutz NP, Ochoa P, Yantorno S, Orlando S, Lopresti S, Zabaljauregui S, Aizpurua F, Shanley C, Giannini E, Garate G, Foncuberta C, Milone J, Riveros D, Fantl D. Duarte PJ, et al. Among authors: zabaljauregui s. Expert Rev Hematol. 2021 Mar;14(3):315-322. doi: 10.1080/17474086.2021.1886073. Epub 2021 Mar 1. Expert Rev Hematol. 2021. PMID: 33541156
Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP, Ochoa P, Duarte P, Remaggi G, Yantorno S, Corzo A, Zabaljauregui S, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga L, García CA, Fernández V, Fantl D. Schütz NP, et al. Among authors: zabaljauregui s. Hematol Oncol. 2020 Aug;38(3):363-371. doi: 10.1002/hon.2729. Epub 2020 Apr 20. Hematol Oncol. 2020. PMID: 32196120
Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.
Peña C, Riva E, Schutz N, Tarín-Arzaga L, Martínez-Cordero H, Bove V, Osorio R, Chandía M, Beltrán C, Schulz J, Cardemil D, Contreras C, Vergara CG, Donoso J, Espinoza M, La Rocca G, López-Vidal H, León P, Rojas Hopkins C, Soto P, Aranda S, Torres V, Roa M, Ochoa P, Duarte PJ, Remaggi G, Yantorno S, Corzo A, Zabaljauregui S, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga L, García C, Fernández V, Ramirez J, Molina A, Pacheco M, Mite A, Reyes I, Sabando B, Ramírez F, Sossa C, Abello V, Idrobo H, Galvez Cardenas KM, Saavedra D, Quintero G, Gazitúa R, Gaviria L, Gomez R, Osuna M, Henao-Uribe A, Cantú-Martínez O, Gómez-Almaguer D, García-Navarrete YI, Cruz-Mora A, Cantero-Fortiz Y, Ruiz-Argüelles GJ, Fantl D. Peña C, et al. Among authors: zabaljauregui s. Leuk Lymphoma. 2020 Dec;61(13):3112-3119. doi: 10.1080/10428194.2020.1804558. Epub 2020 Aug 26. Leuk Lymphoma. 2020. PMID: 32844699